Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low100.00 05/09/17
52 week change -44.75 (-23.40%)
4 week volume460,786 27/09/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Verona Pharma plc : Total voting rights

Verona Pharma plc: Total voting rights October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the issued ordinary share capital of the Company consisted of 105,017,401 ordinary shares with votin...

Best AIM companies of 2017

The annual AIM Awards are almost upon us, so former AIM writer of the year Andrew Hore names the small-cap compa...

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients

Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to Patients Earlier than expected results demonstrate absorption occurs primarily in the lungs following inhaled administration LONDON, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDA...

Verona to issue shares

Verona Pharma has announced that it will issue 133,333 new ordinary shares following an exercise of share options by N+1...

Verona Pharma plc : Miscellaneous

Verona Pharma plc: Miscellaneous Issue of Shares September 19, 2017, London - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will issue 133,333 new ordinary shares in the capital of the Comp...

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva) Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all primary and secondary ef...

Verona Pharma Appoints Stifel as Nominated Adviser

Verona Pharma Appoints Stifel as Nominated Adviser LONDON,Sept. 01, 2017 (GLOBE NEWSWIRE) --Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolau...

Director Deals - Verona Pharma PLC (VRP)

Dr David Ebsworth, Chairman, bought 8,130 shares in the company on the 17th August 2017 at a price of 122.50p. The Direc...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Latest discussion posts More

  • Since ...

    i was referenced on another bb, of which i review now and again and not difficult to follow thread - as here - methinks a certain poster does protest too much! just my ...
    13-Oct-2017
    mol42
  • Abingworth

    recent video here http://www.abingworth.com/portfolio/verona-pharma mol
    12-Oct-2017
    mol42
  • Investor Presentation 091017

    http://investors.veronapharma.com/static-files/6abb3536-6403-4a23-9e3c-a6c617febc28 and whilst spend is increasing (including cost of directors - i know!) we ain't going ...
    12-Oct-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
GULF KEYSTONE10%
RENEURON10%
RANGE RES.10%
BP9%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP